Tobira/Dong-A Partnership Will Add DPP-4 Inhibitor For NASH Combo Therapy
This article was originally published in The Pink Sheet Daily
California biotech acquires rights to Suganon, approved for type 2 diabetes in South Korea, while partner Dong-A gets domestic rights to NASH candidate cenicriviroc.
You may also be interested in...
Intercept continues to lead the non-alcoholic steatohepatitis race, but some analysts think Gilead is making up ground; data presented at AASLD shows those two, along with Allergan/Tobira and Bristol, are jockeying to produce combination regimens for the unmet medical need.
Allergan will pay a huge premium – up to $1.7bn in a milestone-heavy deal – for Tobira and $50m up front for the preclinical startup Akarna to expand its gastrointestinal franchise into the potentially lucrative NASH market.
The brouhaha between Amarin and its largest shareholder has continued apace, with a smorgasbord of verbal volleys launched against the company, ahead of Amarin’s general meeting of shareholders later this month.